Oxindole-Based Inhibitors of Cyclin-Dependent Kinase 2 (CDK2):  Design, Synthesis, Enzymatic Activities, and X-ray Crystallographic Analysis

Two closely related classes of oxindole-based compounds, 1H-indole-2,3-dione 3-phenylhydrazones and 3-(anilinomethylene)-1,3-dihydro-2H-indol-2-ones, were shown to potently inhibit cyclin-dependent kinase 2 (CDK2). The initial lead compound was prepared as a homologue of the 3-benzylidene-1,3-dihydr...

Full description

Saved in:
Bibliographic Details
Published inJournal of medicinal chemistry Vol. 44; no. 25; pp. 4339 - 4358
Main Authors Bramson, H. Neal, Corona, John, Davis, Stephen T, Dickerson, Scott H, Edelstein, Mark, Frye, Stephen V, Gampe, Robert T, Harris, Phil A, Hassell, Anne, Holmes, William D, Hunter, Robert N, Lackey, Karen E, Lovejoy, Brett, Luzzio, Michael J, Montana, Val, Rocque, Warren J, Rusnak, David, Shewchuk, Lisa, Veal, James M, Walker, Duncan H, Kuyper, Lee F
Format Journal Article
LanguageEnglish
Published WASHINGTON American Chemical Society 06.12.2001
Amer Chemical Soc
Subjects
ATP
Online AccessGet full text

Cover

Loading…
More Information
Summary:Two closely related classes of oxindole-based compounds, 1H-indole-2,3-dione 3-phenylhydrazones and 3-(anilinomethylene)-1,3-dihydro-2H-indol-2-ones, were shown to potently inhibit cyclin-dependent kinase 2 (CDK2). The initial lead compound was prepared as a homologue of the 3-benzylidene-1,3-dihydro-2H-indol-2-one class of kinase inhibitor. Crystallographic analysis of the lead compound bound to CDK2 provided the basis for analogue design. A semiautomated method of ligand docking was used to select compounds for synthesis, and a number of compounds with low nanomolar inhibitory activity versus CDK2 were identified. Enzyme binding determinants for several analogues were evaluated by X-ray crystallography. Compounds in this series inhibited CDK2 with a potency ∼10-fold greater than that for CDK1. Members of this class of inhibitor cause an arrest of the cell cycle and have shown potential utility in the prevention of chemotherapy-induced alopecia.
Bibliography:ark:/67375/TPS-60QB7JLT-Q
istex:4EC64EDF31F508A70A0296D067133394A2DAF861
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-2623
1520-4804
DOI:10.1021/jm010117d